Onconic Therapeutics (KRX: 476060)
Who is buying Onconic Therapeutics?
Between Sep 15, 2026 and Oct 16, 2026 (20 trading sessions), foreign investors net bought ₩4.6bn ($3M) of Onconic Therapeutics, the 81st largest foreign net purchase among 1828 KOSDAQ stocks. Institutions net sold ₩0.6bn ($0M) and retail investors net sold ₩4.2bn ($3M) over the same window. Foreigners were net buyers on 11 of the 20 sessions.
Foreign investors hold 0.51% of Onconic Therapeutics' listed shares (KRX ownership data as of Oct 16, 2026), up from 0% twenty sessions earlier and 2.55% a year ago.
The stock closed at ₩13,900 on Oct 16, 2026: -4.99% over 20 sessions, -28.90% year-to-date, -23.42% over one year. The 52-week range is ₩8,790 – ₩28,900.
At ₩13,900 the stock trades at 20.84× current-fiscal-year consensus earnings. The trailing P/E published by KRX is 38.72×, based on the last completed fiscal year.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-16 | ₩13,900 | +₩1.9bn | ₩-0.0bn | ₩-2.0bn |
| 2026-10-15 | ₩12,780 | +₩1.1bn | ₩-0.0bn | ₩-1.0bn |
| 2026-10-14 | ₩13,650 | +₩0.2bn | +₩0.0bn | ₩-0.3bn |
| 2026-10-13 | ₩13,710 | +₩0.5bn | +₩0.0bn | ₩-0.5bn |
| 2026-10-12 | ₩14,220 | +₩0.2bn | +₩0.0bn | ₩-0.2bn |
| 2026-10-08 | ₩14,870 | ₩-0.4bn | ₩-0.0bn | +₩0.6bn |
| 2026-10-07 | ₩15,510 | ₩-0.9bn | ₩-0.0bn | +₩0.9bn |
| 2026-10-06 | ₩15,600 | ₩-0.2bn | +₩0.0bn | +₩0.1bn |
| 2026-10-02 | ₩15,710 | ₩-1.4bn | +₩0.0bn | +₩1.5bn |
| 2026-10-01 | ₩15,920 | +₩3.0bn | +₩0.0bn | ₩-2.9bn |
| 2026-09-30 | ₩15,350 | +₩0.6bn | +₩0.1bn | ₩-0.7bn |
| 2026-09-29 | ₩15,330 | ₩-2.2bn | ₩-0.1bn | +₩1.8bn |
| 2026-09-28 | ₩15,980 | +₩1.4bn | +₩0.1bn | ₩-1.3bn |
| 2026-09-23 | ₩15,130 | ₩-0.5bn | ₩-0.0bn | +₩0.5bn |
| 2026-09-22 | ₩14,730 | ₩-0.5bn | ₩-0.2bn | +₩0.7bn |
| 2026-09-21 | ₩15,050 | +₩0.8bn | ₩-0.0bn | ₩-0.8bn |
| 2026-09-18 | ₩14,860 | ₩-0.3bn | +₩0.0bn | +₩0.2bn |
| 2026-09-17 | ₩15,120 | +₩1.3bn | ₩-0.0bn | ₩-1.3bn |
| 2026-09-16 | ₩14,600 | +₩0.0bn | +₩0.0bn | ₩-0.1bn |
| 2026-09-15 | ₩14,700 | ₩-0.0bn | ₩-0.5bn | +₩0.4bn |
| 2026-09-14 | ₩14,630 | +₩0.7bn | ₩-0.2bn | ₩-0.5bn |
| 2026-09-11 | ₩14,950 | +₩0.8bn | ₩-0.3bn | ₩-0.5bn |
| 2026-09-10 | ₩15,620 | ₩-0.7bn | +₩0.0bn | +₩0.6bn |
| 2026-09-09 | ₩16,090 | +₩0.7bn | +₩0.0bn | ₩-0.7bn |
| 2026-09-08 | ₩16,050 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-09-07 | ₩16,290 | +₩0.0bn | ₩-0.0bn | ₩-0.0bn |
| 2026-09-04 | ₩16,440 | ₩-0.8bn | +₩0.0bn | +₩0.8bn |
| 2026-09-03 | ₩17,110 | ₩-0.6bn | +₩0.0bn | +₩0.7bn |
| 2026-09-02 | ₩16,800 | ₩-1.2bn | ₩-0.0bn | +₩0.9bn |
| 2026-09-01 | ₩17,990 | ₩-1.9bn | ₩-0.0bn | +₩1.9bn |
| 2026-08-31 | ₩18,030 | +₩0.6bn | ₩-0.0bn | ₩-0.4bn |
| 2026-08-28 | ₩14,770 | +₩1.5bn | +₩0.0bn | ₩-1.5bn |
| 2026-08-27 | ₩14,370 | +₩0.1bn | +₩0.1bn | ₩-0.1bn |
| 2026-08-26 | ₩14,460 | ₩-0.3bn | ₩0.0bn | +₩0.0bn |
| 2026-08-25 | ₩14,370 | ₩-0.0bn | +₩0.1bn | +₩0.1bn |
| 2026-08-24 | ₩14,520 | ₩-0.2bn | ₩-0.1bn | +₩0.4bn |
| 2026-08-21 | ₩14,520 | ₩-1.5bn | +₩0.2bn | +₩1.6bn |
| 2026-08-20 | ₩14,730 | +₩0.4bn | ₩-0.5bn | ₩-0.1bn |
| 2026-08-19 | ₩14,000 | +₩0.8bn | ₩-0.4bn | ₩-0.5bn |
| 2026-08-18 | ₩14,250 | +₩0.4bn | ₩-0.0bn | ₩-0.2bn |
| 2026-08-14 | ₩14,810 | ₩-0.8bn | ₩-0.3bn | +₩1.0bn |
| 2026-08-13 | ₩15,480 | ₩-1.0bn | +₩0.0bn | +₩0.6bn |
| 2026-08-12 | ₩15,800 | +₩0.7bn | +₩0.3bn | ₩-0.9bn |
| 2026-08-11 | ₩14,850 | ₩-3.2bn | ₩-0.0bn | +₩3.2bn |
| 2026-08-10 | ₩14,670 | ₩-0.6bn | ₩-0.1bn | +₩0.6bn |
| 2026-08-07 | ₩14,050 | ₩-1.0bn | ₩-0.8bn | +₩1.3bn |
| 2026-08-06 | ₩15,940 | ₩-5.5bn | +₩1.4bn | +₩4.4bn |
| 2026-08-05 | ₩13,030 | +₩1.2bn | ₩-0.0bn | ₩-1.2bn |
| 2026-08-04 | ₩12,650 | ₩-1.6bn | ₩-0.0bn | +₩1.2bn |
| 2026-08-03 | ₩11,240 | ₩-0.2bn | +₩0.0bn | +₩0.1bn |
| 2026-07-31 | ₩10,820 | +₩1.2bn | +₩0.1bn | ₩-1.3bn |
| 2026-07-30 | ₩9,510 | +₩1.4bn | +₩0.0bn | ₩-1.4bn |
| 2026-07-29 | ₩9,520 | +₩0.7bn | ₩-0.0bn | ₩-0.7bn |
| 2026-07-28 | ₩10,310 | +₩0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-07-27 | ₩11,090 | +₩0.5bn | +₩0.0bn | ₩-0.5bn |
| 2026-07-24 | ₩10,940 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-07-23 | ₩11,550 | +₩2.0bn | ₩0.0bn | ₩-2.0bn |
| 2026-07-22 | ₩10,960 | +₩1.0bn | ₩-0.0bn | ₩-1.0bn |
| 2026-07-21 | ₩11,500 | ₩-0.5bn | ₩-1.3bn | +₩1.8bn |
| 2026-07-20 | ₩13,240 | ₩-2.3bn | ₩-0.1bn | +₩2.4bn |
| 2026-07-16 | ₩14,500 | ₩-10.5bn | +₩0.0bn | +₩10.5bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩1.9bn | +$1M | ₩-0.0bn | ₩-2.0bn |
| 5 days | +₩3.9bn | +$3M | ₩-0.0bn | ₩-4.0bn |
| 20 days | +₩4.6bn | +$3M | ₩-0.6bn | ₩-4.2bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Onconic Therapeutics stock?
Over the last 5 sessions foreign investors net bought ₩3.9bn ($3M) of Onconic Therapeutics; over 60 sessions they net sold ₩4.9bn ($4M); since Jan 1, 2026 they net sold ₩11.5bn ($9M). Over 20 sessions the stock is the 81st largest foreign net purchase among 1828 KOSDAQ stocks.
How much of Onconic Therapeutics do foreign investors own?
Foreign investors own 0.51% of Onconic Therapeutics' shares as of Oct 16, 2026, versus 2.55% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩0.6bn ($0M) and retail investors net sold ₩4.2bn ($3M) of Onconic Therapeutics. Foreign buying is being met mainly by retail selling.
Is Onconic Therapeutics listed on KOSPI or KOSDAQ?
Onconic Therapeutics (온코닉테라퓨틱스) trades on KOSDAQ under KRX code 476060 in the Biotech & Pharma group, with a market capitalization of ₩1T ($0.5B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2024 | – | – | -₩5bn (-$4M) | -₩8bn (-$6M) |
| 2025 | – | – | ₩13bn ($9M) | ₩16bn ($12M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1345.9/$) for reference only.